News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
714,658 Results
Type
Article (40999)
Company Profile (300)
Press Release (673358)
Multimedia
Podcasts (88)
Webinars (14)
Section
Business (207211)
Career Advice (2077)
Deals (35913)
Drug Delivery (100)
Drug Development (82491)
Employer Resources (176)
FDA (16329)
Job Trends (15202)
News (350454)
Policy (32942)
Tag
Academia (2576)
Accelerated approval (10)
Adcomms (22)
Allergies (96)
Alliances (50372)
ALS (111)
Alzheimer's disease (1470)
Antibody-drug conjugate (ADC) (160)
Approvals (16322)
Artificial intelligence (319)
Autoimmune disease (29)
Automation (19)
Bankruptcy (364)
Best Places to Work (11757)
BIOSECURE Act (21)
Biosimilars (126)
Biotechnology (212)
Bladder cancer (94)
Brain cancer (37)
Breast cancer (369)
Cancer (2902)
Cardiovascular disease (219)
Career advice (1735)
Career pathing (33)
CAR-T (186)
CDC (33)
Cell therapy (507)
Cervical cancer (22)
Clinical research (67930)
Collaboration (1037)
Company closure (3)
Compensation (698)
Complete response letters (25)
COVID-19 (2649)
CRISPR (57)
C-suite (338)
Cystic fibrosis (114)
Data (3037)
Decentralized trials (2)
Denatured (28)
Depression (66)
Diabetes (347)
Diagnostics (6447)
Digital health (23)
Diversity (10)
Diversity, equity & inclusion (46)
Drug discovery (139)
Drug pricing (127)
Drug shortages (28)
Duchenne muscular dystrophy (132)
Earnings (88511)
Editorial (46)
Employer branding (23)
Employer resources (152)
Events (116220)
Executive appointments (865)
FDA (18002)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (939)
Gene editing (133)
Generative AI (23)
Gene therapy (383)
GLP-1 (815)
Government (4553)
Grass and pollen (5)
Guidances (182)
Healthcare (18925)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (148)
Immuno-oncology (10)
Indications (40)
Infectious disease (2821)
Inflammatory bowel disease (151)
Inflation Reduction Act (11)
Influenza (62)
Intellectual property (121)
Interviews (329)
IPO (16829)
IRA (45)
Job creations (3844)
Job search strategy (1471)
Kidney cancer (13)
Labor market (52)
Layoffs (511)
Leadership (24)
Legal (7979)
Liver cancer (79)
Longevity (12)
Lung cancer (404)
Lymphoma (210)
Machine learning (11)
Management (58)
Manufacturing (396)
MASH (96)
Medical device (13482)
Medtech (13487)
Mergers & acquisitions (19813)
Metabolic disorders (869)
Multiple sclerosis (99)
NASH (16)
Neurodegenerative disease (119)
Neuropsychiatric disorders (35)
Neuroscience (2164)
NextGen: Class of 2025 (6576)
Non-profit (4507)
Now hiring (48)
Obesity (439)
Opinion (237)
Ovarian cancer (102)
Pain (109)
Pancreatic cancer (121)
Parkinson's disease (188)
Partnered (22)
Patents (304)
Patient recruitment (169)
Peanut (50)
People (58571)
Pharmaceutical (76)
Pharmacy benefit managers (22)
Phase I (21202)
Phase II (29979)
Phase III (22195)
Pipeline (1654)
Policy (213)
Postmarket research (2573)
Preclinical (9024)
Press Release (64)
Prostate cancer (141)
Psychedelics (38)
Radiopharmaceuticals (263)
Rare diseases (465)
Real estate (6041)
Recruiting (68)
Regulatory (22912)
Reports (50)
Research institute (2349)
Resumes & cover letters (355)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (88)
Series A (158)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (20)
Spinal muscular atrophy (148)
Sponsored (34)
Startups (3671)
State (2)
Stomach cancer (14)
Supply chain (78)
Tariffs (61)
The Weekly (58)
Vaccines (797)
Venture capital (56)
Weight loss (266)
Women's health (50)
Worklife (20)
Date
Today (77)
Last 7 days (353)
Last 30 days (1876)
Last 365 days (31566)
2025 (17092)
2024 (35731)
2023 (40661)
2022 (51785)
2021 (56339)
2020 (54535)
2019 (46980)
2018 (35385)
2017 (32635)
2016 (32060)
2015 (38110)
2014 (32005)
2013 (26893)
2012 (29013)
2011 (29668)
2010 (27706)
Location
Africa (743)
Alabama (66)
Alaska (7)
Arizona (246)
Arkansas (14)
Asia (39535)
Australia (6372)
California (7502)
Canada (2374)
China (699)
Colorado (324)
Connecticut (323)
Delaware (194)
Europe (85405)
Florida (1135)
Georgia (248)
Hawaii (1)
Idaho (59)
Illinois (642)
India (27)
Indiana (364)
Iowa (17)
Japan (230)
Kansas (109)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1043)
Massachusetts (5614)
Michigan (246)
Minnesota (456)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (81)
New Hampshire (66)
New Jersey (2101)
New Mexico (29)
New York (2107)
North Carolina (1140)
North Dakota (8)
Northern California (3296)
Ohio (238)
Oklahoma (16)
Oregon (35)
Pennsylvania (1620)
Puerto Rico (18)
Rhode Island (36)
South America (1123)
South Carolina (34)
South Dakota (1)
Southern California (2810)
Tennessee (126)
Texas (1139)
United States (27934)
Utah (221)
Virginia (191)
Washington D.C. (73)
Washington State (647)
West Virginia (4)
Wisconsin (66)
714,658 Results for "immix biopharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
July 14, 2025
·
5 min read
Press Releases
Immix Biopharma Attends FDA CEO Forum in Washington DC
June 9, 2025
·
4 min read
Press Releases
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
July 8, 2025
·
5 min read
Press Releases
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
May 23, 2025
·
5 min read
Press Releases
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
April 24, 2025
·
5 min read
Press Releases
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
May 22, 2025
·
7 min read
Press Releases
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
May 23, 2025
·
8 min read
Press Releases
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
June 4, 2025
·
7 min read
Biotech Beach
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
Immix Biopharma, Inc. today announced that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum.
June 17, 2024
·
3 min read
Biotech Beach
Immix Biopharma on Track to Dose NXC-201 Patients in United States
Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that Immix Biopharma is on track to dose NXC-201 patients in the U.S. with no change in patient enrollment timing.
April 18, 2024
·
4 min read
1 of 71,466
Next
